S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:PACB

Pacific Biosciences of California - PACB Stock Forecast, Price & News

$11.58
-0.42 (-3.50%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.27
$12.07
50-Day Range
$7.79
$12.02
52-Week Range
$3.85
$14.20
Volume
4.57 million shs
Average Volume
4.92 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.17

Pacific Biosciences of California MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
35.7% Upside
$15.71 Price Target
Short Interest
Bearish
10.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Pacific Biosciences of California in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$742,461 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.37) to ($1.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

455th out of 1,029 stocks

Analytical Instruments Industry

11th out of 27 stocks

PACB stock logo

About Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Stock News Headlines

“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
PacBio To Launch New Gene-Sequencing Systems
PacBio's (PACB) New Method for TR Profiling Now Available
Pacific Biosciences of California, Inc. (PACB)
PACB Pacific Biosciences of California, Inc.
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Company Calendar

Last Earnings
11/07/2022
Today
2/04/2023
Next Earnings (Confirmed)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
728
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$15.71
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+39.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
6 Analysts

Profitability

Net Income
$-181,220,000.00
Net Margins
-218.44%
Pretax Margin
-217.58%

Debt

Sales & Book Value

Annual Sales
$130.51 million
Book Value
$3.59 per share

Miscellaneous

Free Float
222,943,000
Market Cap
$2.62 billion
Optionable
Optionable
Beta
1.67

Social Links


Key Executives

  • Christian O. HenryChristian O. Henry
    President, Chief Executive Officer & Director
  • Mark David van Oene
    Chief Operating Officer
  • Susan G. KimSusan G. Kim
    Chief Financial Officer
  • Stephen W. Turner
    Chief Technology Officer
  • Jonas Korlach
    Chief Scientific Officer













PACB Stock - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PACB shares.
View PACB analyst ratings
or view top-rated stocks.

What is Pacific Biosciences of California's stock price forecast for 2023?

6 analysts have issued 12-month price objectives for Pacific Biosciences of California's shares. Their PACB share price forecasts range from $8.00 to $40.00. On average, they anticipate the company's share price to reach $15.71 in the next year. This suggests a possible upside of 35.7% from the stock's current price.
View analysts price targets for PACB
or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2023?

Pacific Biosciences of California's stock was trading at $8.18 at the start of the year. Since then, PACB stock has increased by 41.6% and is now trading at $11.58.
View the best growth stocks for 2023 here
.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our PACB earnings forecast
.

How can I listen to Pacific Biosciences of California's earnings call?

Pacific Biosciences of California will be holding an earnings conference call on Thursday, February 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its earnings results on Monday, November, 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. The biotechnology company earned $32.31 million during the quarter, compared to analyst estimates of $35.30 million. Pacific Biosciences of California had a negative net margin of 218.44% and a negative trailing twelve-month return on equity of 42.03%.

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.30 million-$27.30 million, compared to the consensus revenue estimate of $27.88 million.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.36%), Sumitomo Mitsui Trust Holdings Inc. (6.27%), Bourne Lent Asset Management Inc. (0.26%), Simplex Trading LLC (0.00%), State of New Jersey Common Pension Fund D (0.10%) and New York State Common Retirement Fund (0.08%). Insiders that own company stock include Christian O Henry, Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim, Susan K Barnes and William W Ericson.
View institutional ownership trends
.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $11.58.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.62 billion and generates $130.51 million in revenue each year. The biotechnology company earns $-181,220,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

The company employs 728 workers across the globe.

Does Pacific Biosciences of California have any subsidiaries?
The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More
How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.

This page (NASDAQ:PACB) was last updated on 2/4/2023 by MarketBeat.com Staff